Therapeutic antibodies for autoimmunity and inflammation
- PMID: 20414204
- DOI: 10.1038/nri2761
Therapeutic antibodies for autoimmunity and inflammation
Abstract
The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.
Similar articles
-
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date.BioDrugs. 2020 Apr;34(2):111-119. doi: 10.1007/s40259-019-00400-2. BioDrugs. 2020. PMID: 31916225 Review.
-
A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.J Biol Chem. 2018 Jun 15;293(24):9326-9334. doi: 10.1074/jbc.M117.818559. Epub 2018 Apr 20. J Biol Chem. 2018. PMID: 29678878 Free PMC article.
-
The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE.Autoimmun Rev. 2012 Mar;11(5):373. doi: 10.1016/j.autrev.2011.01.002. Epub 2011 Jan 9. Autoimmun Rev. 2012. PMID: 21224014 No abstract available.
-
Strategies and challenges for the next generation of therapeutic antibodies.Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747. Nat Rev Immunol. 2010. PMID: 20414207 Review.
-
[Biological response modifiers in the treatment of immunoinflammatory diseases].Ugeskr Laeger. 2008 Jun 9;170(24):2120-6. Ugeskr Laeger. 2008. PMID: 18565292 Review. Danish.
Cited by
-
Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.Nat Commun. 2024 Apr 10;15(1):3035. doi: 10.1038/s41467-024-47279-4. Nat Commun. 2024. PMID: 38600088 Free PMC article.
-
Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma.Inflamm Res. 2024 May;73(5):841-866. doi: 10.1007/s00011-024-01871-y. Epub 2024 Mar 20. Inflamm Res. 2024. PMID: 38507067
-
Regulation of inflammatory diseases via the control of mRNA decay.Inflamm Regen. 2024 Mar 15;44(1):14. doi: 10.1186/s41232-024-00326-5. Inflamm Regen. 2024. PMID: 38491500 Free PMC article. Review.
-
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.Front Immunol. 2023 Dec 1;14:1291836. doi: 10.3389/fimmu.2023.1291836. eCollection 2023. Front Immunol. 2023. PMID: 38106416 Free PMC article. Review.
-
Bispecific Antibody Detection Using Antigen-Conjugated Synthetic Nucleic Acid Strands.ACS Sens. 2023 Nov 24;8(11):4014-4019. doi: 10.1021/acssensors.3c01717. Epub 2023 Oct 19. ACS Sens. 2023. PMID: 37856082 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous